Literature DB >> 16918439

Cannabinoids, immune system and cytokine network.

P Massi1, A Vaccani, D Parolaro.   

Abstract

How cannabinoids influence immune function has been examined extensively in the last 30 years. Studies on drug-abusing humans and animals, as well as in vitro models employing immune cell cultures, have shown that marijuana, natural and endogenous cannabinoid compounds are immunomodulators. These substances modulate host resistance to bacterial, protozoan and viral infections as well as they can profoundly affect the Th1/Th2 response. Recently, two types of cannabinoid receptor, CB1 and CB2, have been discovered. While CB1 is expressed primarily in the brain, CB2 is peculiar of the immune cells. Cannabinoid receptors have been shown to be involved in some but not all of immune effects. Nevertheless, their identification provides a specific mechanism of action in the attempting to find out how exogenous cannabinoids and endogenous cannabinoid system affect the immune apparatus, strengthen the hypothesis of cannabinoids as immunomodulators. As support to this theory, enough evidence exists to suggest that the cannabinoid system significantly affects almost every component of the immune response machinery and impacts the functioning also of the cytokine network. The evaluation of the biological consequences of these drug-induced cytokine changes has also dramatically become important considering not only the impact of cytokines on immune system per se but also envisaging their influence in cancer, inflammation, autoimmune disease, brain injury, hematopoietic colony formation in which cannabinoids have demonstrated a clear role as important modulators.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918439     DOI: 10.2174/138161206777947425

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  25 in total

1.  Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippocampus Similar to that Observed for Peripheral Macrophages.

Authors:  Sarah Moretti; Silvia Franchi; Mara Castelli; Giada Amodeo; Lorenzo Somaini; Alberto Panerai; Paola Sacerdote
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-10       Impact factor: 4.147

2.  A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.

Authors:  Alysia N Lozano-Ondoua; Courtney Wright; Anna Vardanyan; Tamara King; Tally M Largent-Milnes; Mark Nelson; Juan Miguel Jimenez-Andrade; Patrick W Mantyh; Todd W Vanderah
Journal:  Life Sci       Date:  2010-02-20       Impact factor: 5.037

3.  Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.

Authors:  Joseph E Henriquez; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2019-02-23       Impact factor: 4.219

Review 4.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

5.  Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.

Authors:  Jessica M Sido; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Leukoc Biol       Date:  2015-06-01       Impact factor: 4.962

6.  The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.

Authors:  J M Jamontt; A Molleman; R G Pertwee; M E Parsons
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

7.  Δ9-Tetrahydrocannabinol Suppresses Secretion of IFNα by Plasmacytoid Dendritic Cells From Healthy and HIV-Infected Individuals.

Authors:  Joseph E Henriquez; Michael D Rizzo; Matthias A Schulz; Robert B Crawford; Peter Gulick; Norbert E Kaminski
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

8.  Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

Authors:  Alysia N Lozano-Ondoua; Katherine E Hanlon; Ashley M Symons-Liguori; Tally M Largent-Milnes; Josh J Havelin; Henry L Ferland; Anupama Chandramouli; Mabel Owusu-Ankomah; Tijana Nikolich-Zugich; Aaron P Bloom; Juan Miguel Jimenez-Andrade; Tamara King; Frank Porreca; Mark A Nelson; Patrick W Mantyh; Todd W Vanderah
Journal:  J Bone Miner Res       Date:  2013-01       Impact factor: 6.741

9.  Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.

Authors:  Carl Potenzieri; Thaddeus S Brink; Cholawat Pacharinsak; Donald A Simone
Journal:  J Neurophysiol       Date:  2008-09-10       Impact factor: 2.714

Review 10.  Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Neuropsychopharmacology       Date:  2016-09-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.